XXXX . Case report.

@entity1 @entity4438 @entity6 @entity13675 @entity5 @entity75 @entity2 @entity189 @entity272 @entity3 @entity1030 @entity158 @entity420
@entity2 is the most common @entity5 diagnosed worldwide. Metastatic presentation of the disease is frequent. Apart from the usual sites of @entity3 (bone, adrenals, liver, brain), a particular site for @entity3 is represented by skin. The case we report is about a 66 year-old @entity1 with cutaneous @entity3 from @entity2 . A 66 year-old @entity1 , with a previous history of abdominal aortic aneurism, @entity1030 , @entity13675 , @entity6 , was admitted to our institution for @entity2 . After accurate preoperative @entity5 , @entity1 underwent a thoracotomic left lower lobectomy. Histological examination revealed a @entity189 : G2-3, pT2bN0. @entity1 underwent oncological evaluation for the scheduled follow up. After 6 months @entity1 went back to our observation for the appearance of a skin nodule, firm, dischromic, @entity158 and ulcerated, localized in right iliac fossa. Biopsies demonstrated the nodule to be @entity189 . @entity1 underwent a CT scan of the abdomen and thorax, which revealed the absence of @entity4438 by the @entity5 . @entity1 underwent surgical @entity75 . Final histological examination confirmed the lesion to be @entity3 of squamocellular @entity2 . @entity3 from @entity2 occur in about 2,5-7,5% of cases. Median survival for these @entity1 is 2,9 months. The most common type of @entity5 , according to Japanese Authors, is @entity420 followed by @entity189 . Some studies demonstrated the adequacy of surgery followed by chemotherapy, in case of single lesion. In case of multiple cutaneous @entity3 , many Authors suggest only chemotherapy, although the ideal scheme hasn't been discovered yet. Cutaneous @entity3 from @entity2 are rare; however the appearance of @entity272 , in @entity1 with a positive oncological history, requires much attention. Accurate evaluation of the @entity1 is paramount in choosing the adequate therapeutic algorithm. KEY WORDS: Chemotherapy, @entity2 , Skin @entity3 .
